新型コロナウイルス感染症（COVID-19）の重症化を予防するためのモルヌピラビルの臨床試験（MK-4482-023）

基本情報

NCT ID

NCT06667700

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

3,082

治験依頼者名

Merck Sharp & Dohme LLC

概要

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect. Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)